T
Toshiaki Toyota
Researcher at Kyoto University
Publications - 47
Citations - 1114
Toshiaki Toyota is an academic researcher from Kyoto University. The author has contributed to research in topics: Medicine & Percutaneous coronary intervention. The author has an hindex of 12, co-authored 33 publications receiving 767 citations. Previous affiliations of Toshiaki Toyota include Massachusetts Institute of Technology.
Papers
More filters
Journal ArticleDOI
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial
Hirotoshi Watanabe,Takenori Domei,Takeshi Morimoto,Masahiro Natsuaki,Hiroki Shiomi,Toshiaki Toyota,Masanobu Ohya,Satoru Suwa,Kensuke Takagi,Mamoru Nanasato,Yoshiki Hata,Masahiro Yagi,Nobuhiro Suematsu,Takafumi Yokomatsu,Itaru Takamisawa,Masayuki Doi,Toshiyuki Noda,Hideki Okayama,Yoshitane Seino,Tomohisa Tada,Hiroki Sakamoto,Kiyoshi Hibi,Mitsuru Abe,Kazuya Kawai,Koichi Nakao,Kenji Ando,Kengo Tanabe,Yuji Ikari,Keiichi Igarashi Hanaoka,Yoshihiro Morino,Ken Kozuma,Kazushige Kadota,Yutaka Furukawa,Yoshihisa Nakagawa,Takeshi Kimura +34 more
TL;DR: It is suggested that a shorter duration of DAPT may provide benefit, although given study limitations, additional research is needed in other populations.
Journal ArticleDOI
Adenosine triphosphate-guided pulmonary vein isolation for atrial fibrillation: the UNmasking Dormant Electrical Reconduction by Adenosine TriPhosphate (UNDER-ATP) trial.
Atsushi Kobori,Satoshi Shizuta,Koichi Inoue,Kazuaki Kaitani,Takeshi Morimoto,Yuko Nakazawa,Tomoya Ozawa,T Kurotobi,I Morishima,Fumiharu Miura,T Watanabe,Masaharu Masuda,Masaki Naito,Hajime Fujimoto,Taku Nishida,Yoshio Furukawa,Takeshi Shirayama,M Tanaka,Katsunori Okajima,Takenori Yao,Yasuyuki Egami,Kazuhiro Satomi,Takashi Noda,Koji Miyamoto,Tetsuya Haruna,Tetsuma Kawaji,Takashi Yoshizawa,Toshiaki Toyota,Mitsuhiko Yahata,Kentaro Nakai,Hiroaki Sugiyama,Yukei Higashi,Makoto Ito,Minoru Horie,Kengo Kusano,Wataru Shimizu,Shiro Kamakura,Takeshi Kimura +37 more
TL;DR: In the catheter ablation for AF, there was no significant reduction in the 1-year incidence of recurrent atrial tachyarrhythmias by ATP-guided PVI compared with conventional PVI.
Journal ArticleDOI
Efficacy of Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial Fibrillation (EAST-AF) trial.
Kazuaki Kaitani,Koichi Inoue,Atsushi Kobori,Yuko Nakazawa,Tomoya Ozawa,T Kurotobi,I Morishima,Fumiharu Miura,T Watanabe,Masaharu Masuda,Masaki Naito,Hajime Fujimoto,Taku Nishida,Yoshio Furukawa,Takeshi Shirayama,M Tanaka,Katsunori Okajima,Takenori Yao,Yasuyuki Egami,Kazuhiro Satomi,Takashi Noda,Koji Miyamoto,Tetsuya Haruna,Tetsuma Kawaji,Takashi Yoshizawa,Toshiaki Toyota,Mitsuhiko Yahata,Kentaro Nakai,Hiroaki Sugiyama,Yukei Higashi,Makoto Ito,Minoru Horie,Kengo Kusano,Wataru Shimizu,Shiro Kamakura,Takeshi Morimoto,Takeshi Kimura,Satoshi Shizuta +37 more
TL;DR: Short-term use of AAD for 90 days following AF ablation reduced the incidence of recurrent atrial tachyarrhythmias during the treatment period, but it did not lead to improved clinical outcomes at the later phase.
Journal ArticleDOI
Very Late Scaffold Thrombosis of Bioresorbable Vascular Scaffold: Systematic Review and a Meta-Analysis
Toshiaki Toyota,Takeshi Morimoto,Hiroki Shiomi,Yusuke Yoshikawa,Hidenori Yaku,Yugo Yamashita,Takeshi Kimura +6 more
TL;DR: BVS as compared with EES was associated with higher risk for VLST between 1 and 2 years and ST through 2 years, a meta-analysis of 24 studies found.
Journal ArticleDOI
Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial.
Hirotoshi Watanabe,Takenori Domei,Takeshi Morimoto,Masahiro Natsuaki,Hiroki Shiomi,Toshiaki Toyota,Masanobu Ohya,Satoru Suwa,Kensuke Takagi,Mamoru Nanasato,Yoshiki Hata,Masahiro Yagi,Nobuhiro Suematsu,Takafumi Yokomatsu,Itaru Takamisawa,Masayuki Doi,Toshiyuki Noda,Hideki Okayama,Yoshitane Seino,Tomohisa Tada,Hiroki Sakamoto,Kiyoshi Hibi,Mitsuru Abe,Kazuya Kawai,Koichi Nakao,Kenji Ando,Kengo Tanabe,Yuji Ikari,Keiichi Igarashi Hanaoka,Yoshihiro Morino,Ken Kozuma,Kazushige Kadota,Yutaka Furukawa,Yoshihisa Nakagawa,Takeshi Kimura,Stopdapt Investigators +35 more
TL;DR: The effect of 1-month dual antiplatelet therapy (DAPT) for the primary and major secondary endpoints were consistent in HBR and non-HBR patients without any significant interactions and the benefit of 2-month DAPT in reducing major bleeding was numerically greater in H BR patients.